Tipsheet
What matters at India’s listed companies

NIBE's Vayu Astra-1 passes Army trials with 100 km range, sub-2-metre accuracy

The micro-cap defence firm, battling a 60% revenue drop, now has a validated loitering munition that could unlock procurement orders.

1 earlier story on NIBE Ltd.
Mkt cap₹2,170 cr
ROE11.52%
Debt / eq.0.32
Div yld0.09%
100 km Range of Vayu Astra-1 loitering munition in Army trials.

What's new

  • NIBE successfully completes technical trials for Vayu Astra-1 loitering munition against Indian Army RFP.
  • Trials demonstrate 100 km range, sub-2-metre CEP, and over 90 minutes high-altitude endurance.
  • Achievement comes amid a 60% revenue decline and net losses for the micro-cap defence firm.

Why this matters

For a company with a recent 60% revenue decline, this trial output is a lifeline. Validated indigenous loitering munitions are scarce; NIBE now has a product the Army may order from. The question is how quickly procurement converts into revenue — and whether the company's stretched finances can sustain operations until then.

What we're watching

  • Whether the Army issues a procurement order following the successful trials.
  • NIBE's ability to convert this validated technology into revenue given its recent financial strain.
  • Any competitor responses or parallel trials from other loitering munition developers.

The full read

NIBE's Vayu Astra-1 loitering munition has passed its most critical test yet — technical trials against a live Indian Army RFP. The micro-cap defence company, which saw revenues shrink 60% in its latest reported period and is carrying net losses, now has a product that hits the spec: 100 km range, sub-2-metre circular error probable, and over 90 minutes of high-altitude endurance. The trials also included safe recovery, a detail that matters for combat reusability. This is not an order — it's a qualification. But in the Indian defence ecosystem, a validated indigenously developed loitering munition is a rarity. If the Army proceeds to procurement, NIBE's revenue visibility changes entirely. The challenge is timing: the company's cash position and recent losses leave little room for a long gap between trial success and purchase order. What's on the table now is NIBE's most credible shot at turning around.

Mentioned: Indian Army · Vayu Astra-1 Loitering Munition · ₹1,799 cr market cap
Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Story so far

All notes on NIBE →
  1. Today · 12:42 PM IST NIBE's Vayu Astra-1 passes Army trials with 100 km range, sub-2-metre accuracy
  2. today NIBE opens a massive defence plant in Shirdi for artillery shells.